<DOC>
	<DOCNO>NCT00320320</DOCNO>
	<brief_summary>The purpose study evaluate feasibility efficacy first-line FOLFIRI discontinuation initial 8 cycle reintroduction progression .</brief_summary>
	<brief_title>Irinotecan Discontinuation Reintroduction Advanced Colorectal Cancer</brief_title>
	<detailed_description>For medically-fit patient advanced colorectal cancer , current standard approach chemotherapy FOLFIRI FOLFOX . Although strategy use sequential 5-FU , irinotecan oxaliplatin think maximize overall survival patient , significant toxicity remain problem . It suggest feasible chemotherapy discontinue 2-3 month restart treatment progression patient chemosensitive colorectal cancer . Thus design pilot phase II study evaluate feasibility efficacy first-line FOLFIRI discontinuation initial 8 cycle reintroduction progression .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically proven adenocarcinoma colon rectum No prior chemotherapy adjuvant chemotherapy and/or radiotherapy Advanced , metastatic recurrent amenable curative local therapy Measurable lesion ( ) ECOG performance status 0 2 Normal marrow , hepatic renal function Provision write informed consent Active infection and/or severe comorbidity Known history anaphylaxis origin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>No prior chemotherapy</keyword>
</DOC>